PhRMA To Assist Pay-For-Locate Trial Enrollment Tool To Boost Study Diversity
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA takes an active role in shaping a new National Clinical Trial Network that aims to speed up enrollment of diverse study populations as FDA increases its push for minorities in clinical research.
You may also be interested in...
PhRMA’s “I’m In” Campaign Looks To Connect Minorities To Studies
Extension of the Clinical Trial Engagement Network is aimed at increased diversity in clinical trials, which is becoming increasingly important as more drugs are targeted at specific groups.
Jonca Bull Brings Clinical Experience To FDA Minority Health Office
Bull returns to the agency after stints at Novartis and Genentech to become director of the Office of Minority Health.
Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle
Vertex Pharmaceuticals' Incivek (telaprevir) has cleared FDA with labeling advantages that should enable it to win a majority of patients in the battle against Merck's competing protease inhibitor for hepatitis C, Victrelis (boceprevir).